Theravance, after clinical setbacks, agrees to $929M buyout
Theravance, after clinical setbacks, agrees to $929M buyout. (BioPharma Dive.)
Theravance Biopharma
Theravance Biopharma is a specialty biopharmaceutical company focused on respiratory diseases, commercializing YUPELRI (revefenacin) for COPD through a Viatris partnership, with a research pipeline targeting lung disease.
Company Info
Sector:Small Molecule Pharma
Headquarters:South San Francisco, California, United States
Founded:2013
Website:www.theravance.com/
Upcoming Milestones & Key Dates
2026-08
Earnings
Q2 2026 Earnings Call
2026-Q3
Corporate
Zymeworks acquisition close
Clinical Development Pipeline
YUPELRI (revefenacin)
Target: Long-acting muscarinic antagonistAmpreloxetine (TD-9855)
Target: Norepinephrine transporterTD-8236
Target: Inhaled JAK inhibitorRecent News
After trial fail, Teravance is bought out by Zymeworks for $929M
Zymeworks is acquiring Theravance Biopharma in a $929 million deal, taking out the struggling drugmaker after a Phase 3 failure of its lead respiratory candidate.
Theravance, after clinical setbacks, agrees to $929M buyout
Theravance, after clinical setbacks, agrees to $929M buyout (BioPharma Dive.)
Leadership Team
Rick E Winningham
Chairman and Chief Executive Officer
Rhonda S. Farnum
Chief Administrative Officer
Andrew A. Guglielmi
Senior Vice President, Operations
Careers & Job Openings